Doctors stunned after promising heart drug fails major study

Medical professionals are stunned following the results of a major study involving a Novartis heart drug. Although the medication successfully lowered lipoprotein(a), which is identified as a genetic heart risk factor, it failed to achieve its primary goals. The study revealed that the drug did not reduce the occurrence of heart attacks, strokes, or cardiovascular deaths. This outcome is unexpected given the initial promise of the treatment in managing critical cardiovascular health risks for patients.